The downgrade from Buy to Neutral and the significant reduction in the price target from $5 to $1 by B. Riley Securities suggests a negative short-term outlook for Cognition Therapeutics. This is likely to result in a decline in the stock price as investors react to the less favorable analyst rating and lower price target.